OncohematologyOncohematologyОнкогематология1818-83462413-4023Publishing House ABV Press56410.17650/1818-8346-2022-17-3-108-113THEORETICAL AND CONTROVERSIAL ASPECTS IN ONCOLOGYТЕОРЕТИЧЕСКИЕ И ДИСКУТАБЕЛЬНЫЕ АСПЕКТЫ В ОНКОЛОГИИDisputable questions of statins antitumor effects in hemoblastosesДискутабельные вопросы противоопухолевых эффектов статинов при гемобластозахhttps://orcid.org/0000-0002-4091-382XMustafinR. N.МустафинР. Н.
Russian Federation

Rustam N. Mustafin.

3 Lenina St., Ufa 450008.

Мустафин Рустам Наилевич.

450008 Уфа, ул. Ленина, 3.

ruji79@mail.ruBashkir State Medical University, Ministry of Health of RussiaБашкирский государственный медицинский университет Минздрава России200720221731081132007202220072022https://oncohematology.abvpress.ru/ongm/article/view/564

Antitumor drug treatment of hemoblastoses always takes into account the patient comorbidity. Due to the frequent cardiovascular pathology and atherosclerosis, patients have to take statins along with antitumor treatment. Experimental studies have shown that statins inhibit the cholesterol synthesis (necessary for the vital activity of malignant cells), isoprenylation of the RAS and RHO oncogenes, and the proliferation of leukemic cells. In addition, the potentiation of antitumor drugs effect by statins, sensitization of leukemia and lymphomas cells to their effects were noted. when conducting a meta-analysis, it was found that mortality among patients with hematological malignancies taking statins is lower compared with the group of patients not receiving statins. This fact is probably explained not only by the improvement in cholesterol metabolism, but also by indirect antitumor effects of this group of drugs.

Противоопухолевое лекарственное лечение гемобластозов всегда учитывает коморбидный фон пациента. В связи с частой сердечно-сосудистой патологией и атеросклерозом пациентам наряду с противоопухолевым лечением приходится принимать статины. В экспериментальных работах было показано, что статины ингибируют синтез холестерина (необходимого для жизнедеятельности злокачественных клеток), изопренилирование онкогенов RAS и RHO , пролиферацию лейкемических клеток. кроме этого, отмечены потенцирование статинами эффекта противоопухолевых препаратов, сенсибилизирование клеток лейкоза и лимфом к их воздействию. при проведении метаанализа установлено, что смертность среди больных гемобластозами, принимающих статины, ниже по сравнению с группой пациентов, не получающих статины. Вероятно, данный факт объясняется не только улучшением показателей холестеринового обмена, но и косвенными противоопухолевыми эффектами данной группы лекарственных препаратов.

apoptosishemoblastosismalignancyleukemiamevalonate pathwayprenylationstatinscholesterolапоптозгемобластоззлокачественное новообразованиелейкозмевалонатный путьпренилированиестатиныхолестеринAleskerova G.A., Shervashidze M.A., Popa A.V. et al. Results of acute lymphoblastic leukemia treatment in children according to the ALL IC-BFM 2002 protocol. Onkopediatriya = Oncopediatrics 2016;3(4):302-8. (In Russ.).Алескерова Г.А., Шервашидзе М.А., Попа А.В. и др. Результаты лечения острого лимфобластного лейкоза у детей по протоколу ALL IC-BFM 2002. Онкопедиатрия 2016;3(4):302-8.Shervashidze M.A., Valiev T.T. Pediatric acute lymphoblastic leukemia treatment protocols improvement: emphasis on minimal residual disease. Onkogematologiya = Oncohematology 2020;15(3):12-26. (In Russ.). DOI: 10.17650/1818-83462020-15-3-12-26Шервашидзе М.А., Валиев Т.Т. Совершенствование программ терапии острого лимфобластного лейкоза у детей: акцент на минимальную остаточную болезнь. Онкогематология 2020;15(3):12—26. DOI: 10.17650/1818-83462020-15-3-12-26Chow S., Buckstein R., Spaner D.E. A link between hypercholesterolemia and chronic lymphocytic leukemia. Leuk Lymphoma 2016;57(4):797-802. DOI: 10.3109/10428194.2015.1088651McCaw L., Shi Y., Wang G. et al. Low density lipoproteins amplify cytokinesignaling in chronic lymphocytic leukemia cells. EBioMedicine 2017;15:24-35. DOI: 10.1016/j.ebiom.2016.11.033Militaru A., Avram A., Cimpean A.M. et al. The assessment of left ventricle function and subclinical atherosclerosis in patients with acute myeloid leukemia. In Vivo 2018;32(6):1599-607. DOI: 10.21873/invivo.11420Elbaek M.V., Sorensen A.L., Hasselbalch H.C. Cardiovascular disease in chronic myelomonocytic leukemia: do monocytosis and chronic inflammation predispose to accelerated atherosclerosis. Ann Hematol 2019;98(1):101-9. DOI: 10.1007/s00277-018-3489-0Wethal T., Nedregaard B., Andersen R. et al. Atherosclerotic lesions in lymphoma survivors treated with radiotherapy. Radiother Oncol 2014;110(3):448-54. DOI: 10.1016/j.radonc.2013.10.029Cepelova M., Kruseova J., Luks A. Accelerated atherosclerosis, hyperlipoproteinemia and insulin resistance in long-term survivors of Hodgkin lymphoma during childhood and adolescence. Neoplasma 2019;66(6):978-87. DOI: 10.4149/neo_2019_190115N45Mullen P.J., Rosemary Yu., Longo J. et al. The interplay between cell signaling and the mevalonate pathway in cancer. Nat Rev Cancer 2016;16(11):718-31. DOI: 10.1038/nrc.2016.76Endo A., Kuroda M., Tanzawa K. Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ML-236A and ML-236B fungal metabolites, having hypocholesterolemic activity. FEBS Lett 1976;72(2):323-6. DOI: 10.1016/0014-5793(76)80996-9Alberts A.W., Chen J., Kuron G. et al. Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. Proc Natl Acad Sci USA 1980;77(7):3957-61. DOI: 10.1073/pnas.77.7.3957Yamamoto A., Sudo H., Endo A. Therapeutic effects of ML-236B in primary hypercholesterolemia. Atherosclerosis 1980;35(3):259-66. DOI: 10.1016/0021-9150(80)90124-0Bathaie S.Z., Ashrafi M., Azizian M., Tamanoi F. Mevalonate pathway and human cancers. Curr Mol Pharmacol 2017;10(2):77-85. DOI: 10.2174/1874467209666160112123205Nielsen S.F., Nordestgaard B.G., Bojesen S.E. Statin use and reduced cancer-related mortality. N Engl J Med 2012;367(19):1792-802. DOI: 10.1056/NEJMoa1201735Yang J., Li C., Shen Y. et al. Impact of statin use on cancer-specific mortality and recurrence: a meta-analysis of 60 observational studies. Medicine (Baltimore) 2020;99(14):e19596. DOI: 10.1097/MD.0000000000019596Branvall E., Ekberg S., Eloranta S. et al. Statin use and survival in 16098 patients with non-Hodgkin lymphoma or chronic lymphocytic teukaemia treated in the rituximab era. Br J Haematol 2021;195(4):552-60. DOI: 10.1111/bjh.17733Pradelli D., Soranna D., Zambon A. et al. Statins use and the risk of all and subtype hematological malignancies: a metaanalysis of observational studies. Cancer Med 2015;4(5):770-80. DOI: 10.1002/cam4.411Ye X., Mneina A., Johnston J.B., Mahmud S.M. Associations between statin use and non-Hodgkin lymphoma (NHL) risk and survival: a meta-analysis. Hematol Oncol 2017;35(2):206-14. DOI: 10.1002/hon.2265Kim J., You N.Y., Lee J.W. et al. Inverse association between statin use and overall cancer incidence in individuals with hypercholesterolemia, based on the Korean health insurance servive between 2002 and 2015. Asia Pac J Public Health 2019;31(2):136-46. DOI: 10.1177/1010539519830235Righolt C.H., Zhang G., Ye X. et al. Statin use and chronic lymphocytic leukemia incidence: a nested case-control study in Manitoba, Canada. Cancer Epidemiol Biomarkers Prev 2019;28(9):1495-501. DOI: 10.1158/1055-9965.EPI-19-0107Chapman-Shimshoni D., Yuklea M., Radnay J. et al. Simvastatin induces apoptosis of B-CLL cells by activation of mitochondrial caspase 9. Exp Hematol 2003;31(9):779-83. DOI: 10.1016/s0301-472x(03)00192-9Tomiyama N., Matzno S., Kitada C. et al. The possibility of simvastatin as a chemotherapeutic agent for all-trans retinoic acid-resistant promyelocytic leukemia. Biol Pharm Bull 2008;31(3):369-74. DOI: 101248/bpb.31.369Infante E., Heasman S.J., Ridley A.J. Statin inhibit T-acute lymphoblastic leukemia cell adhesion and migration through Rap1b. J Leukoc Biol 2011;89(4):577-86. DOI: 10.1189/jlb.0810441Yang S.S., Li R., Qu X. et al. Atorvastatin decreases Toll-like receptor 4 expression and downstream signaling in human monocytic leukemia cells. Cell Immunol 2012;279(1):96-102. DOI: 10.1016/j.cellimm.2012.09.008Vilimanovich U., Bosnjak M., Bogdanovic A. et al. Statin-mediated inhibition of cholesterol synthesis induces cytoprotective autophagy in human leukemic cells. Eur J Pharmacol 2015;765:415-28. DOI: 10.1016/j.ejphar.2015.09.004Jang J., Lee J., Jang J.H. et al. Anti-leukemic effects of simvastatin on NRASG12D mutant acute myeloid leukemia cells. Mol Biol Rep 2019;46(6):5859-66. DOI: 10.1007/s11033-019-05019-8Crosbie J., Magnussen M., Dornbier R. et al. Statins inhibit proliferation and cytotoxicity of a human leukemic natural killer cell line. Biomark Res 2013;1(1):33. DOI: 10.1186/2050-7771-1-3Krosl J., Bordeleau M.E., Moison C. et al. Vesicular trafficking is a key determinant of the statin response in acute myeloid leukemia. Blood 2022;6(2):509-14. DOI: 10.1182/bloodadvances.2021006047Ahmed T.A., Hayslip J., Leggas M. Simvastatin interacts synergistically with tipifarnib to induce apoptosis in leukemia cells through the disruption of RAS membrane localization and ERK pathway inhibition. Leuk Res 2014;38(11):1350-7. DOI: 10.1016/j.leukres.2014.09.002Sassano A., Katsoulidis E., Antico G. et al. Suppressive effects of statins on acute promyelocytic leukemia cells. Cancer Res 2007;67(9):4524-32. DOI: 10.1158/0008-5472.CAN-06-3686Tian H., Qiang T., Wang J. et al. Simvastatin regulates the proliferation, apoptosis, migration and invasion of human acute myeloid leukemia cells via miR-19a-3p/HIF-1a axis. Bioengineered 2021;12(2):11898-908. DOI: 10.1080/21655979.2021.1999552Henslee A.B., Steele T.A. Combination statin and chemotherapy inhibits proliferation and cytotoxicity of an aggressive natural killer cell leukemia. Biomark Res 2018;6:26. DOI: 10.1186/s40364-018-0140-0Seregin G.Z., Lifshits A.V., Aleskerova G.A., Valiev T.T. Possibilities of epigenetic therapy for acute myeloid leukemia in children. Sovremennaya onkologiya = Modern Oncology 2019;21(4):15-20. (In Russ.).Серегин Г.З., Лифшиц А.В., Алескерова Г.А., Валиев Т.Т. Возможности эпигенетической терапии острых миелоидных лейкозов у детей. Современная онкология 2019;21(4):15-20.Chae Y.K., Trinh L., Jain P. et al. Statin and aspirin use is associated with improved outcome of FCR therapy in relapsed/refractory chronic lymphocytic leukemia. Blood 2014;123(9):1424-6. DOI: 10.1182/blood-2013-07-517102Gimenez N., Tripathi R., Giro A. et al. Systems biology drug screening identifies statins as enhancers of current therapies in chronic lymphpcytic leukemia. Sci Rep 2020;10(1):22153. DOI: 10.1038/s41598-020-78315-0Jang H.J., Woo Y.M., Naka K. et al. Statins enhance the molecular response in chronic myeloid leukemia when combined with tyrosine kinase inhibitors. Cancers (Basel) 2021;13(21):5543. DOI: 10.3390/cancers13215543Ageberg M., Rydstrom K., Linden O. et al. Inhibition of geranylgeranylation mediates sensitivity to CHOP-induced cell death of DLBCL cell lines. Exp Cell Res 2011;317(8):1179-91. DOI: 10.1016/j.yexcr.2011.02.006Smyth L., Blunt D.N., Gatov E. et al. Statin and cyclooxygenase-2 inhibitors improve survival in newly diagnosed diffuse large B-cell lymphoma: a large populationbased study of 4913 subjects. Br J Haematol 2020;191(3):396-404. DOI: 10.1111/bjh.16635Baryakh E.A., Tyurina N.G., Vorob'ev V.I. et al. Twelve-year experience in the treatment of Burkitt's lymphoma according to the LB-M-04 protocol. Terapevticheskiy arkhiv = Therapeutic Archive 2015;87(7):4-14. (In Russ.).Барях Е.А., Тюрина Н.Г., Воробьев В.И. и др. Двенадцатилетний опыт терапии лимфомы Беркитта по протоколу ЛБ-М-04. Терапевтический архив 2015;87(7):4-14.Valiev T.T. Burkitt's lymphoma in children: 30 years of therapy. Pediatriya. Zhurnal im. G.N. Speranckogo = Pediatrics. Journal named after G.N. Speranskiy 2020;99(4):35-41. (In Russ.).Валиев Т.Т. Лимфома Беркитта у детей: 30 лет терапии. Педиатрия. Журнал им. Г.Н. Сперанского 2020;99(4):35-41.